title: Thromboprophylaxis with the low-molecular-weight heparin bemiparin sodium in elderly medical patients in usual clinical practice: the ANCIANOS study.
abstract: BACKGROUND
  Venous thromboembolism (VTE) is a preventable common disease in geriatric medical patients, causing substantial morbidity and mortality.
  
  
  OBJECTIVE
  To assess the effectiveness and safety of bemiparin sodium thromboprophylaxis in non-surgical elderly medical patients (aged > or =65 years) bedridden for at least 4 days due to acute medical illness. This was a prospective, observational, multicentre cohort study carried out in patients treated in the setting of geriatric centres (GCs) or hospital-at-home units (HHUs). The study included 507 non-surgical elderly patients recruited from 49 Spanish centres who were administered subcutaneous bemiparin sodium (Hibor) 2500 IU/day or 3500 IU/day, depending on the degree of VTE risk - moderate or high, respectively. Rates of VTE, major and minor bleeding events, thrombocytopenia and deaths that occurred during the 3-month study period were extracted.
  
  
  RESULTS
  Seventy-two percent of the subjects were women, and the mean (SD) age was 82 (8) years. Overall, 70.6% (358 patients) were treated in GCs and 29.4% (149 patients) in HHUs. The main causes of immobilization were: heart failure (30.4%), acute infectious disease (29.8%), acute respiratory insufficiency (19.9%), rheumatological disease (i.e. osteoarthritis, rheumatoid arthritis and osteoporosis) [15.4%] and acute cerebrovascular disease (14.4%). Most of the patients (63%) had a high VTE risk and received the highest dose of prophylactic bemiparin sodium (3500 IU/day) for a mean 33 days. The incidence of VTE was 0.6% (three distal deep vein thromboses confirmed by Doppler ultrasound). No cases of pulmonary embolism were reported. There were two (0.4%) major bleeding events, eight (1.6%) minor bleeding events and seven (1.4%) cases of mild thrombocytopenia; no cases of moderate or severe thrombocytopenia were reported. Twenty-four patients (4.7%) developed mild to moderate injection site complications. Twenty-one patients (4.1%) died, but all from causes not related to study medication.
  
  
  CONCLUSIONS
  Bemiparin sodium thromboprophylaxis for 4-5 weeks was associated with a low incidence of VTE and a low rate of bleeding and other complications in non-surgical elderly patients at risk of VTE, treated either in GCs or in HHUs, in standard clinical practice.
authors.affiliation: Geriatrics Service and Research Unit, Hospital Universitario de Getafe, Getafe, Spain. lrodriguez.hugf@madrid.org
authors.forename: Leocadio
authors.initials: L
authors.lastname: Rodríguez-Mañas
authors.forename: Ricardo
authors.initials: R
authors.lastname: Gómez-Huelgas
authors.forename: Fernando
authors.initials: F
authors.lastname: Veiga-Fernández
authors.forename: Gema Monteagudo
authors.initials: GM
authors.lastname: Ruiz
authors.forename: Javier Martínez
authors.initials: JM
authors.lastname: González
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006299:Health Services for the Aged; D006470:Hemorrhage / Q000139:chemically induced; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D018575:Home Care Services, Hospital-Based; D006801:Humans; D008297:Male; D011446:Prospective Studies; D012307:Risk Factors; D013030:Spain; D054556:Venous Thromboembolism / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; C411345:bemiparin
references.citation: Thromb Haemost. 2004 Mar;91(3):538-43
references.pmid: 14983230
references.citation: J Gen Intern Med. 2003 Nov;18(11):934-6
references.pmid: 14687280
references.citation: J Am Geriatr Soc. 2002 Aug;50(8):1439-45; discussion 1446-7
references.pmid: 12165003
references.citation: BMJ. 2006 Feb 11;332(7537):325-9
references.pmid: 16439370
references.citation: BMJ. 1997 Oct 25;315(7115):1059
references.pmid: 9366735
references.citation: N Engl J Med. 1999 Sep 9;341(11):793-800
references.pmid: 10477777
references.citation: Presse Med. 2001 Jan 27;30(3):101-6
references.pmid: 11225477
references.citation: Arch Intern Med. 2007 Jul 23;167(14):1471-5
references.pmid: 17646600
references.citation: Expert Opin Pharmacother. 2003 Sep;4(9):1551-61
references.pmid: 12943485
references.citation: J Am Geriatr Soc. 2003 Oct;51(10):1472-8
references.pmid: 14511171
references.citation: Clin Drug Investig. 2005;25(7):463-72
references.pmid: 17532688
references.citation: Int J Clin Pract. 2005 May;59(5):555-61
references.pmid: 15857352
references.citation: Clin Interv Aging. 2007;2(2):237-46
references.pmid: 18044139
references.citation: Arch Intern Med. 2007 Jul 23;167(14):1476-86
references.pmid: 17646601
references.citation: J Intern Med. 2006 Aug;260(2):168-76
references.pmid: 16882282
references.citation: Arch Intern Med. 2004 May 10;164(9):963-8
references.pmid: 15136304
references.citation: Clin Interv Aging. 2008;3(3):399-411
references.pmid: 18982911
references.citation: J Mal Vasc. 2009 Nov;34(5):330-7
references.pmid: 19625147
references.citation: Wien Med Wochenschr. 2004 Apr;154(7-8):159-62
references.pmid: 15182042
references.citation: J Am Geriatr Soc. 1996 May;44(5):603-5
references.pmid: 8617915
references.citation: Arch Intern Med. 2004 Nov 8;164(20):2260-5
references.pmid: 15534164
references.citation: BMJ. 1992 Sep 5;305(6853):567-74
references.pmid: 1298229
references.citation: Arch Intern Med. 2005 Feb 14;165(3):341-5
references.pmid: 15710801
references.citation: Acta Neurol Scand Suppl. 2000;176:96-9
references.pmid: 11261812
references.citation: J Thromb Haemost. 2007 Jul;5 Suppl 1:310-7
references.pmid: 17635742
references.citation: Arch Intern Med. 2003 Nov 24;163(21):2613-8
references.pmid: 14638561
references.citation: Haematologica. 2006 Aug;91(8):1046-51
references.pmid: 16885044
references.citation: Chest. 2008 Jun;133(6 Suppl):381S-453S
references.pmid: 18574271